In last trading session, Enlivex Therapeutics Ltd (NASDAQ:ENLV) saw 0.26 million shares changing hands with its beta currently measuring 1.00. Company’s recent per share price level of $1.14 trading at $0.07 or 6.54% at ring of the bell on the day assigns it a market valuation of $24.40M. That closing price of ENLV’s stock is at a discount of -302.63% from its 52-week high price of $4.59 and is indicating a premium of 28.95% from its 52-week low price of $0.81. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.22 million shares which gives us an average trading volume of 149.50K if we extend that period to 3-months.
For Enlivex Therapeutics Ltd (ENLV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.16 in the current quarter.
Enlivex Therapeutics Ltd (NASDAQ:ENLV) trade information
Upright in the green during last session for gaining 6.54%, in the last five days ENLV remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $1.14 price level, adding 1.72% to its value on the day. Enlivex Therapeutics Ltd’s shares saw a change of -57.78% in year-to-date performance and have moved 16.80% in past 5-day. Enlivex Therapeutics Ltd (NASDAQ:ENLV) showed a performance of -20.28% in past 30-days. Number of shares sold short was 99233.0 shares which calculate 0.56 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 92.4% to its current value. Analysts have been projecting 15 as a low price target for the stock while placing it at a high target of 15. It follows that stock’s current price would drop -1215.79% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1215.79% for stock’s current value.
Enlivex Therapeutics Ltd (ENLV) estimates and forecasts
Statistics highlight that Enlivex Therapeutics Ltd is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -15.55% of value to its shares in past 6 months, showing an annual growth rate of 55.13% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.51% during past 5 years.
Enlivex Therapeutics Ltd (NASDAQ:ENLV)’s Major holders
ARMISTICE CAPITAL, LLC is the top institutional holder at ENLV for having 1.7 million shares of worth $2.41 million. And as of 2024-06-30, it was holding 9.0808 of the company’s outstanding shares.
The second largest institutional holder is MORGAN STANLEY, which was holding about 0.24 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.3077 of outstanding shares, having a total worth of $0.35 million.
